Investigational drug · Phase 3
FXS6837
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "FXS6837"
First trial start
2026
Mar 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FXS6837", any sponsor or status.
Conditions studied
As listed on its trial records.
- Paroxysmal Nocturnal Hemoglobinuria
- Primary IgAN
- IgAN
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "FXS6837" as an intervention, largest first.
- A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.Pivotal-lookingNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07747090 · 90 participants (planned) · Start Dec 10, 2026 · Primary completion May 5, 2028
Drug: FXS6837 Capsule; Eculizumab infusion · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China
- FXS6837 for the Treatment of IgAN PatientsNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07502638 · 60 participants (planned) · Start Mar 31, 2026 · Primary completion Sep 12, 2027
Drug: FXS6837 Dose 1; FXS6837 Dose 2 and 1 more · For: IgAN
Sites: Beijing, China
- FXS6837 for the Treatment for IgAN Patients(Longterm Study)Not yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07750665 · 60 participants (planned) · Start Sep 30, 2026 · Primary completion Nov 13, 2029
Drug: FXS6837 Capsule · For: Primary IgAN
Sites: Beijing, China
- A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTIONNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07949799 · 24 participants (planned) · Start Dec 17, 2026 · Primary completion Apr 29, 2027
Drug: FXS6837 capsule · For: Hepatic Impairment
- A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.Pivotal-lookingNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07914894 · 20 participants (planned) · Start Jan 26, 2027 · Primary completion May 17, 2028
Drug: FXS6837 Capsule · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Hangzhou, China; Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Paroxysmal Nocturnal Hemoglobinuria
- HRS-5965Phase 36 trials
Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- NTQ5082Phase 34 trials
Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- LP-005Phase 24 trials
Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.